GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (OTCPK:LBPWQ) » Definitions » NonCurrent Deferred Liabilities

4d pharma (4d pharma) NonCurrent Deferred Liabilities : $0.00 Mil (As of Dec. 2021)


View and export this data going back to 2021. Start your Free Trial

What is 4d pharma NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

4d pharma's non-current deferred liabilities for the quarter that ended in Dec. 2021 was $0.00 Mil.

4d pharma NonCurrent Deferred Liabilities Historical Data

The historical data trend for 4d pharma's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4d pharma NonCurrent Deferred Liabilities Chart

4d pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial - - - - -

4d pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

4d pharma NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of 4d pharma's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


4d pharma (4d pharma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ
4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.

4d pharma (4d pharma) Headlines

From GuruFocus

4D pharma plc ("4D pharma") Receives Notice of Delisting From Nasdaq

By Business Wire Business Wire 06-28-2022

4D pharma to Participate in Ladenburg Thalmann Healthcare Conference

By Business Wire Business Wire 06-29-2021

4D pharma to Present at the H.C. Wainwright BioConnect Conference

By Business Wire Business Wire 01-05-2022